CN115380050A - 针对alppl2和/或alpp的抗原结合分子及其用途 - Google Patents

针对alppl2和/或alpp的抗原结合分子及其用途 Download PDF

Info

Publication number
CN115380050A
CN115380050A CN202180017750.8A CN202180017750A CN115380050A CN 115380050 A CN115380050 A CN 115380050A CN 202180017750 A CN202180017750 A CN 202180017750A CN 115380050 A CN115380050 A CN 115380050A
Authority
CN
China
Prior art keywords
ser
thr
gly
ala
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180017750.8A
Other languages
English (en)
Chinese (zh)
Inventor
W·孙
陈文炜
王华晶
叶泰梁
方馨忆
汪正一
黄庆文
李雪婷
万嘉辉
黄健端
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of CN115380050A publication Critical patent/CN115380050A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180017750.8A 2020-02-07 2021-02-05 针对alppl2和/或alpp的抗原结合分子及其用途 Pending CN115380050A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202001139U 2020-02-07
SG10202001139U 2020-02-07
PCT/SG2021/050061 WO2021158178A1 (en) 2020-02-07 2021-02-05 Antigen-binding molecules against alppl2 and/or alpp and uses thereof

Publications (1)

Publication Number Publication Date
CN115380050A true CN115380050A (zh) 2022-11-22

Family

ID=77199411

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180017750.8A Pending CN115380050A (zh) 2020-02-07 2021-02-05 针对alppl2和/或alpp的抗原结合分子及其用途

Country Status (19)

Country Link
US (1) US20230080224A1 (https=)
EP (1) EP4100443A4 (https=)
JP (2) JP2023512827A (https=)
KR (1) KR20220139930A (https=)
CN (1) CN115380050A (https=)
AU (1) AU2021217919A1 (https=)
BR (1) BR112022015540A2 (https=)
CA (1) CA3170141A1 (https=)
CL (3) CL2022002114A1 (https=)
CO (1) CO2022011944A2 (https=)
CR (1) CR20220441A (https=)
DO (2) DOP2022000159A (https=)
EC (1) ECSP22061867A (https=)
IL (1) IL295291A (https=)
JO (1) JOP20220175A1 (https=)
MX (1) MX2022009709A (https=)
PE (1) PE20221781A1 (https=)
PH (1) PH12022552038A1 (https=)
WO (1) WO2021158178A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120882866A (zh) * 2022-12-21 2025-10-31 阿尔麦克探索有限公司 Alpp特异性变体抗原结合分子

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120014958A1 (en) * 2008-06-25 2012-01-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
WO2017095823A1 (en) * 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
WO2017204277A1 (ja) * 2016-05-27 2017-11-30 国立大学法人東京大学 抗ＴＧＦ－ｂｅｔａ３抗体およびその使用
CN108088997A (zh) * 2016-11-21 2018-05-29 同济大学 利用细胞表面分子标志物鉴定人类原态多能性的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120014958A1 (en) * 2008-06-25 2012-01-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
WO2017095823A1 (en) * 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
WO2017204277A1 (ja) * 2016-05-27 2017-11-30 国立大学法人東京大学 抗ＴＧＦ－ｂｅｔａ３抗体およびその使用
CN108088997A (zh) * 2016-11-21 2018-05-29 同济大学 利用细胞表面分子标志物鉴定人类原态多能性的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LANNING, D.等: ""IgG heavy chain VDJ region, partial [Oryctolagus cuniculus]"", 《GENBANK》, 26 July 2016 (2016-07-26), pages 98336 *
POPKOV, M.等: ""antibody variable domain, partial [Oryctolagus cuniculus]"", 《GENBANK》, 24 July 2016 (2016-07-24), pages 06493 *
YANG SU 等: ""ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen"", 《CANCER RES》, 8 January 2020 (2020-01-08), pages 10 *
高健鹏 等: ""抗胃癌单克隆抗体MS57-2.1的鉴定及其生物学功能的研究"", 《第9届全国胃癌学术会议暨第二届阳光长城肿瘤学术会议论文汇编》, 27 June 2014 (2014-06-27), pages 117 *

Also Published As

Publication number Publication date
IL295291A (en) 2022-10-01
CR20220441A (es) 2022-12-14
PE20221781A1 (es) 2022-11-16
JP2023512827A (ja) 2023-03-29
CL2024002073A1 (es) 2025-01-10
CO2022011944A2 (es) 2022-08-30
WO2021158178A1 (en) 2021-08-12
MX2022009709A (es) 2022-09-09
AU2021217919A1 (en) 2022-09-29
KR20220139930A (ko) 2022-10-17
PH12022552038A1 (en) 2023-11-29
DOP2022000159A (es) 2022-09-30
DOP2025000135A (es) 2025-07-15
JP2026027248A (ja) 2026-02-18
CL2024002074A1 (es) 2025-01-10
EP4100443A1 (en) 2022-12-14
JOP20220175A1 (ar) 2022-07-28
EP4100443A4 (en) 2024-05-15
BR112022015540A2 (pt) 2022-12-27
US20230080224A1 (en) 2023-03-16
CL2022002114A1 (es) 2023-03-03
ECSP22061867A (es) 2022-09-30
CA3170141A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
JP2024036342A (ja) Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用
JP2020018298A (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
KR20210018800A (ko) 암 치료를 위한 항-oxMIF/항-CD3 항체
JP7851303B2 (ja) ヒトｃｄ３イプシロンに結合する新規なヒト抗体
JP2024504471A (ja) Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
JP2026027248A (ja) 抗原結合分子およびその使用
WO2024140932A1 (en) Anti-b7h3 antibodies and methods of use
US20260028421A1 (en) Antigen-binding molecule specifically binding to gucy2c and cd3 and pharmaceutical use thereof
WO2024184812A1 (en) Anti-cldn6 antibodies and methods of use
EA049990B1 (ru) Антигенсвязывающие молекулы против alppl2 и/или alpp и их применение
US20240301062A1 (en) Anti-cd3 multispecific antibodies and methods of use
US20240301061A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
US20240301051A1 (en) Anti-cldn6 antibodies and methods of use
WO2024153168A2 (en) Anti-cmet antibodies and methods of use
WO2025254591A1 (en) Anti-ceacam antigen-binding molecules
WO2024184811A1 (en) Anti-cd3 multispecific antibodies and methods of use
WO2024184810A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2025207033A1 (en) Anti-trop2 antigen-binding molecules
AU2024237990A1 (en) Anti-b7h3 antibodies and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination